These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26739573)

  • 1. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.
    Thamrongwonglert P; Chetchotisakd P; Anunnatsiri S; Mootsikapun P
    HIV Clin Trials; 2016 Feb; 17(1):12-6. PubMed ID: 26739573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
    Phongsamart W; Jantarabenjakul W; Chantaratin S; Anugulruengkitt S; Suntarattiwong P; Sirikutt P; Kosalaraksa P; Maleesatharn A; Chokephaibulkit K
    J Int AIDS Soc; 2022 Jan; 25(1):e25862. PubMed ID: 35001501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.
    Jantarabenjakul W; Anugulruengkitt S; Kasipong N; Thammajaruk N; Sophonphan J; Bunupuradah T; Cressey TR; Colbers A; Burger DM; Phongsamart W; Puthanakit T; Pancharoen C;
    Antivir Ther; 2018; 23(3):259-265. PubMed ID: 28994660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
    Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
    Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
    AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
    Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
    Gazaignes S; Resche-Rigon M; Gatey C; Yang C; Denis B; Fonsart J; Desseaux K; Guionie M; Rozenbaum W; Delaugerre C; Molina JM
    Antivir Ther; 2016; 21(4):329-36. PubMed ID: 26566057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study.
    Rokx C; Blonk M; Verbon A; Burger D; Rijnders BJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19789. PubMed ID: 25397533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
    Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
    HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
    Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.